Correspondence 0001104659-23-089795 from Adlai Nortye Ltd. (ANL)
Adlai Nortye Ltd.
Date: Aug. 10, 2023 · CIK: 0001944552 · Accession: 0001104659-23-089795
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273465
Letter
Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Re: Adlai Nortye Ltd. CIK No. 0001944552 Registration Statement on Form F-1 (File No. 333-273465)
Dear Ms. Do, Ms. Connell, Mr. McNamara, and Ms. Crotty:
On behalf of our client, Adlai Nortye Ltd., a foreign private issuer organized under the laws of the Cayman Islands (the “Company”), we are filing herewith Amendment No. 1 to the Company’s registration statement on Form F-1 (the “Registration Statement”) containing a preliminary prospectus with an estimated price range and certain exhibits via EDGAR with the Securities and Exchange Commission (the “Commission”).
Furthermore, in compliance with the filing procedures mandated by the China Securities Regulatory Commission (“CSRC”), the Company has amended the necessary disclosures. The CSRC published a notification regarding the successful completion of the required filing procedures for this offering on August 7, 2023.
The Company respectfully advises the staff of the Commission (the “Staff”) that the Company plans to commence the road show for the proposed offering shortly hereafter, and request that the Staff declare the effectiveness of the Registration Statement on or before August 17, 2023. The Company, together with the underwriters, will file joint acceleration requests in time before the requested effective time. The Company would greatly appreciate the Staff’s continuing assistance and support to the Company in meeting the proposed timetable for the offering.
* * *
Austin • Century City • Dallas • Los Angeles • Newport Beach • New York • San Francisco • Silicon Valley • Washington, DC
Beijing • Brussels • Hong Kong • London • Seoul • Shanghai • Singapore • Tokyo
If you have any questions regarding the Registration Statement, please contact the undersigned at +86 13910939617 / +86 10 6563 4261 / kgeng@omm.com, Vincent Lin of O’Melveny & Myers LLP at +86 13601656082 / +86 21 2307 7068 / vlin@omm.com, or Howard Leung, partner at Mazars USA LLP, at (347) 831-1871 / howard.leung@mazarsusa.com. Mazars USA LLP is the independent registered public accounting firm of the Company.
Very truly yours,
/s/ Ke Geng
Show Raw Text
CORRESP
1
filename1.htm
O’Melveny & Myers LLP
T: +86 10 6563 4200
Yin Tai Centre, Office Tower
F: +86 10 6563 4201
37th Floor
omm.com
No.2 Jianguomenwai Avenue
Beijing 100022
People’s Republic of China
August 10, 2023
CONFIDENTIAL
Ms. Jenn Do
Ms. Angela Connell
Mr. Jimmy McNamara
Ms. Laura Crotty
Division of Corporation Finance
Life Sciences
United States Securities and Exchange
Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Adlai Nortye Ltd.
CIK No. 0001944552
Registration Statement on Form F-1 (File No. 333-273465)
Dear
Ms. Do, Ms. Connell, Mr. McNamara, and Ms. Crotty:
On behalf of our client, Adlai
Nortye Ltd., a foreign private issuer organized under the laws of the Cayman Islands (the “Company”), we are filing
herewith Amendment No. 1 to the Company’s registration statement on Form F-1 (the “Registration Statement”)
containing a preliminary prospectus with an estimated price range and certain exhibits via EDGAR with the Securities and Exchange Commission
(the “Commission”).
Furthermore, in compliance
with the filing procedures mandated by the China Securities Regulatory Commission (“CSRC”), the Company has amended
the necessary disclosures. The CSRC published a notification regarding the successful completion of the required filing procedures for
this offering on August 7, 2023.
The Company respectfully advises
the staff of the Commission (the “Staff”) that the Company plans to commence the road show for the proposed offering
shortly hereafter, and request that the Staff declare the effectiveness of the Registration Statement on or before August 17, 2023.
The Company, together with the underwriters, will file joint acceleration requests in time before the requested effective time. The Company
would greatly appreciate the Staff’s continuing assistance and support to the Company in meeting the proposed timetable for the
offering.
* * *
Austin • Century
City • Dallas • Los Angeles • Newport Beach • New York • San Francisco • Silicon Valley • Washington,
DC
Beijing • Brussels
• Hong Kong • London • Seoul • Shanghai • Singapore • Tokyo
1
If
you have any questions regarding the Registration Statement, please contact the undersigned at +86 13910939617 / +86 10 6563 4261
/ kgeng@omm.com, Vincent Lin of O’Melveny & Myers LLP at +86 13601656082 / +86 21 2307 7068 / vlin@omm.com, or Howard
Leung, partner at Mazars USA LLP, at (347) 831-1871 / howard.leung@mazarsusa.com. Mazars USA LLP is the independent registered public
accounting firm of the Company.
Very truly yours,
/s/ Ke Geng
Ke Geng
Enclosures
cc:
Yang Lu, Director, Chief Executive Officer, Chairman of the Board of
the Company
Lars Erik Birgerson, President, Chief Medical Officer of the Company
Wei Zhang, Chief Financial Officer of the Company
Ke Geng, Esq., Partner, O’Melveny & Myers LLP
Allen C. Wang, Esq., Partner, Latham & Watkins LLP
Austin • Century
City • Dallas • Los Angeles • Newport Beach • New York • San Francisco • Silicon Valley • Washington,
DC
Beijing • Brussels
• Hong Kong • London • Seoul • Shanghai • Singapore • Tokyo
2